Kite, a Gilead Company, is set to present 18 presentations at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting the strength of its CAR T-cell therapy portfolio across a spectrum of blood cancers. Key data include positive survival outcomes with Yescarta and Tecartus, and promising results for anito-cel in relapsed/refractory multiple myeloma.
Anito-cel Data in Multiple Myeloma
Arcellx, in collaboration with Kite, will present data on anitocabtagene autoleucel (anito-cel) from a Phase 1 study demonstrating a 30.2-month median progression-free survival (PFS) with a median follow-up of 38.1 months. Preliminary results from 58 patients in the Phase 2 iMMagine-1 study show a 95% objective response rate (ORR) and a 62% complete response / stringent complete response (CR/sCR) at a median follow-up of 10.3 months. These studies highlight durable responses in patients with relapsed or refractory (R/R) multiple myeloma (MM) with no delayed neurotoxicities observed.
Positive Survival Outcomes with Yescarta
Key presentations for Yescarta (axicabtagene ciloleucel) include a five-year follow-up analysis from ZUMA-5 evaluating response rate and long-term survival in patients with R/R indolent non-Hodgkin lymphoma (iNHL), including follicular lymphoma and marginal zone lymphoma. Yescarta has demonstrated superior overall survival versus standard therapy for patients with early R/R large B-cell lymphoma (LBCL), as seen in the largest real-world analysis of patients with R/R LBCL who received second-line Yescarta.
Tecartus Demonstrates Durable Responses
Key presentations for Tecartus (brexucabtagene autoleucel) include five-year outcomes from ZUMA-2 cohorts 1 and 2 and a primary analysis of ZUMA-2 cohort 3, highlighting durable responses in adult patients with R/R mantle cell lymphoma (MCL). Tecartus continues to deliver unprecedented efficacy in R/R MCL three years after its approval. Real-world outcomes in adults with R/R B-cell precursor acute lymphoblastic leukemia (B-ALL) treated with Tecartus will also be presented, highlighting the CAR T-cell therapy’s high effectiveness in a broader R/R B-ALL patient population.
Advancements in Kite’s Pipeline
Advancements in Kite’s pipeline will also be highlighted, including data presented on Kite’s next generation CAR T-cell therapy KITE-753, an autologous anti-CD19/CD20 CAR T-cell therapy for the treatment of B-cell malignancies.
Dominique Tonelli, M.D., VP, Global Head of Medical Affairs, Kite, stated, “Our data underscore our commitment to helping people with blood cancers live longer and demonstrate the benefit of CAR T-cell therapy as a mainstay of blood cancer treatment. Notably for this year, along with our partner Arcellx, we are excited to share clinically meaningful data from the Phase 1 study and the iMMagine-1 Phase 2 registrational study of anito-cel for the treatment of relapsed/refractory multiple myeloma.”
